Anton Rx Report

………….. catching up on FDA Approvals Here’s what we wrote back in July….. The FDA recently approved a biosimilar….. big news…… huh? But wait….. on the same

PBMs have been increasingly under the regulatory microscope for some time…. and recent focus has never been more intense. The pushback from the industry has also

…………catching up on FDA approvals The FDA has approved a new therapy, Pyzchiva (ustekinumab-ttwe) from Samsung Bioepis, as a biosimilar to Janssen Biotech’s Stelara. Pyzchiva is

Artificial Intelligence (AI) is one of the leading topics in media today. But, for many people AI is about as easy to explain as Crypto Currency.

Earlier this week we sent a Report on Walmart opening twenty-five specialty pharmacies. That was about organic growth. Today we are reporting on the changing hands

……….. catching up on FDA Approvals The FDA recently approved a new therapy, Ohtuvayre (ensifentrine) from Verona Pharma plc, for the maintenance treatment of chronic obstructive

……….catching up on FDA approvals We usually don’t report on expanded indications for a therapy previously approved by the FDA. This time one such approval

We’ve written about Value-Based Contracting (VBC) numerous times.  The logic of VBC is self-evident.  However, the feasibility and implementation of VBC is a totally different

The FDA recently approved a new infused therapy, Rytelo (imetelstat) from Geron Corporation, for the treatment of adult patients with low – to intermediate-1 risk

In the third century BCE a wonder of the world, the Colossus of Rhodes, stood as testament to ever lasting power and strength. As history tells,